

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (3)

- Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.
- Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
- Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).

Exclusion (10)

- Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to
 - gastric bypass
 - sleeve gastrectomy
 - restrictive bariatric surgery, such as Lap-Band gastric banding, or
 - any other procedure intended to result in weight reduction.
- ... and 5 more (see full listing online)

Locations (75 total)

Children's Hospital Los Angeles, Los Angeles, California, United States
Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology, Sacramento, California, United States
Nemours Children's Health - Delaware, Wilmington, Delaware, United States
... and 72 more locations